Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder Oct 18, 2022 04:05PM
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code Sep 5, 2022 10:19PM
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction Aug 18, 2022 04:05PM
Clarus Therapeutics (CRXT) Announces Notice of Allowance for Additional Patent Claims Covering JATENZO Jul 28, 2022 09:05AM
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate) Jul 28, 2022 09:05AM


Jun 9, 2022 09:05AM Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
May 18, 2022 09:06AM Clarus Therapeutics (CRXT) Announces Issuance of Patent Covering JATENZO
May 18, 2022 09:05AM Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
May 16, 2022 04:05PM Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 12, 2022 09:05AM Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
May 10, 2022 09:06AM Clarus Therapeutics (CRXT) Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
May 10, 2022 09:05AM Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
May 9, 2022 09:05AM Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
Apr 28, 2022 09:05AM Clarus Therapeutics (CRXT) Receives Notice of Allowance for Patent Claims Covering JATENZO
Apr 28, 2022 09:05AM Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
Apr 27, 2022 01:43PM Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
Apr 25, 2022 09:21AM Clarus Therapeutics (CRXT) Prices 26.68M Unit Offering at $1.10/unit
Apr 25, 2022 09:20AM Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
Apr 19, 2022 09:05AM Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting
Mar 30, 2022 04:05PM Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Mar 29, 2022 04:05PM Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
Mar 16, 2022 09:06AM Clarus Therapeutics (CRXT) Announces Phase 4 Clinical Trial of JATENZO for the Treatment of Hypogonadal Men with Chronic Kidney Disease
Mar 16, 2022 09:05AM Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease
Mar 10, 2022 09:05AM Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
Feb 24, 2022 08:00AM Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients
Jan 18, 2022 09:07AM Clarus Therapeutics (CRXT) Appoints Zhanna Jumadilova as Chief Clinical Development Officer
Jan 18, 2022 09:05AM Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer
Nov 30, 2021 09:05AM Clarus Therapeutics (CRXT) Issues Two New Patents for JATENZO
Nov 30, 2021 09:05AM Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
Nov 18, 2021 04:05PM Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
Nov 17, 2021 04:05PM Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
Oct 26, 2021 09:06AM Clarus Therapeutics (CRXT) Announces Two New Patents for JATENZO
Oct 26, 2021 09:05AM Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
Oct 14, 2021 09:05AM Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
Sep 22, 2021 09:05AM Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
Sep 16, 2021 09:05AM Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) De
Sep 15, 2021 09:05AM Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Sep 9, 2021 12:46PM Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies